Drug Profile
Glofitamab - Roche
Alternative Names: aCD20/CD3 TCB 2; aCD20/CD3 TCBs; Anti-CD20 CD3 TCB; Anti-CD20/CD3 bispecific monoclonal antibody; CD20-TCB; COLUMVI; Columvi; Glofitamab-gxbm; RG 6026; RG6026-2; RO 7082859Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Diffuse large B cell lymphoma
- Phase III B-cell lymphoma; Mantle-cell lymphoma
- Phase II Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
- Phase I Haematological malignancies
Most Recent Events
- 15 Apr 2024 Efficacy and adverse events data from the phase III STARGLO trial in Diffuse large B cell lymphoma released by Genentech
- 28 Feb 2024 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Second-line therapy or greater) in China (IV, Injection)
- 15 Feb 2024 Roche announces intention to submit regulatory filing for Mantle-cell lymphoma (Refractory metastatic disease, Second-line therapy or greater) in or after 2026 (Roche pipeline, February 2024)